Memphis-based biopharmaceutical company GTx Inc. has reported net loss of $10.7 million for the fourth quarter ended Dec. 31 compared to a similar $10.7 million net loss in Q4 2011.

2. GTx Drug Receives Fast-Track Status From FDA - Saturday, January 12, 2013

An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration’s fast-track program.

3. GTx Drug Receives Fast-Track Status From FDA - Wednesday, January 09, 2013

An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration’s fast-track program.

4. GTx Drug Receives Fast-Track Status From FDA - Tuesday, January 08, 2013

MEMPHIS (AP) – An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration's fast-track program. Its shares climbed more than 12 percent in premarket trading.

5. GTx Rebounds in Third Quarter - Friday, November 09, 2012

Memphis-based biopharmaceutical company GTx Inc. on Thursday, Nov. 8, reported net income of $7.4 million for the third quarter, fueled primarily from $18.8 million in net proceeds from the sale in early October of Fareston, a breast treatment medication.

6. Entrepreneurial Ecosystem - Monday, October 01, 2012

Maybe you’re a startup founder who wants to rub shoulders with your peers, pitch investors in the hope of landing venture capital and talk to a lawyer about drawing up paperwork.

Maybe you’re a veteran researcher who’s got a side project that looks like it could turn into something big. Or maybe you’ve got little more than an idea on the back of a napkin.

7. GTx Narrows Q2 Loss - Thursday, August 09, 2012

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

8. GTx Narrows Q2 Loss - Wednesday, August 08, 2012

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

9. UTHSC Breaks Ground On Research Building - Monday, June 11, 2012

The University of Tennessee Health Science Center broke ground Friday, June 8, on its $49 million Translational Science Research Building, which will be built on the grassy lot at the northwest corner of Union Avenue and South Manassas Street.

10. Hill Joins Barge, Waggoner, Sumner & Cannon as CFO - Wednesday, May 23, 2012

Certified Public Accountant Jason Hill has joined engineering and architectural firm Barge, Waggoner, Sumner & Cannon Inc. as chief financial officer.

11. UTHSC Prof. Receives $325K For Drug Discovery Instrument - Wednesday, May 09, 2012

Dr. Wei Li, associate professor in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC), is the principal investigator of a $325,000 grant from the Office of the Director, a subsidiary of the National Institutes of Health.

12. GTx Reports $11.1 Million Q1 Net Income Loss - Wednesday, May 09, 2012

Memphis-based biopharmaceutical company GTx Inc. on Tuesday, May 8, reported an $11.1 million net loss for the first quarter, compared to a net loss of $2.6 million for the same period in 2011.

13. Steiner, GTx Inc. Prepare For Next Step of Journey - Monday, April 16, 2012

Dr. Mitchell Steiner recently returned from a trip to Eastern Europe, where he visited hospitals participating in international clinical trials for the drug enobosarm, which is being developed by his Memphis-based public biopharmaceutical company GTx Inc.

14. Many Questions Raised Before Going Public - Monday, April 16, 2012

As Facebook prepares for its multibillion-dollar initial public offering (IPO) next month, it sheds light on how companies – including local ones – decide whether to go public or not.

Memphis-based pharmaceutical company GTx Inc. went public in 2004 and local paper producer Verso Paper Corp. held its IPO in 2008, but the overall number of publicly traded companies both locally and nationally has dropped over the past two decades.

15. Performance Of Memphis Public Cos. Varies Widely - Monday, April 16, 2012

Memphis is home to several publicly traded companies that have made an indelible mark on industries ranging from transportation to finance and manufacturing.

Here’s a snapshot of how those companies are faring at the moment. (For a detailed look at AutoZone, see related story, "The Fast Lane.")

16. GTx Sends FDA Info on Prostate Drug - Thursday, April 05, 2012

GTx Inc. said Wednesday, April 4, that it is starting discussions with the U.S. Food and Drug Administration about resuming trials of its experimental prostate cancer drug Capesaris.

17. Ambitious Growth on Tap For Med Communications - Monday, March 05, 2012

Pharmaceutical consulting firm Med Communications Inc. is expanding its presence in Memphis, with plans to soon move into a larger office space to accommodate anticipated growth over the next several years.

18. Panel: State Has ‘Robust’ Bioscience Community - Monday, February 27, 2012

Members of the region’s scientific, medical, academic and business communities seeking more knowledge about innovative early-stage investment strategies in the biosciences packed the ballroom of The University Club, 1346 Central Avenue, on Thursday, Feb. 23, for a panel discussion hosted by Memphis Bioworks Business Association.

19. FDA Places Hold on GTx Study as Company Reports Earnings Drop - Wednesday, February 22, 2012

Memphis-based pharmaceutical company GTx Inc. on Tuesday, Feb. 21, announced that the U.S. Food and Drug Administration had placed a clinical hold on the company’s Phase II clinical studies for Capesaris.

20. FDA Places Hold on GTx Study as Company Reports Earnings Drop - Tuesday, February 21, 2012

Memphis-based pharmaceutical company GTx Inc. on Tuesday, Feb. 21, announced that the U.S. Food and Drug Administration had placed a clinical hold on the company’s Phase II clinical studies for Capesaris.

21. GTx Shares Up Sharply After Citigroup Report - Thursday, February 02, 2012

Shares of GTx Inc. rose about 50 percent Monday, Jan. 30, after Citigroup predicted the Memphis-based pharmaceutical company was likely about a year away from reporting positive results from its Phase III clinical trials for Ostarine, a drug designed to prevent and treat muscle wasting in cancer patients.

22. GTx Shares Rise 50 Pct. After Positive Citigroup Report - Wednesday, February 01, 2012

Shares of GTx Inc. rose about 50 percent Monday, Jan. 30, after Citigroup predicted the Memphis-based pharmaceutical company was likely about a year away from reporting positive results from its Phase III clinical trials for Ostarine, a drug designed to prevent and treat muscle wasting in cancer patients.

23. Biz Community Still Seeking Stable Ground - Thursday, December 29, 2011

Small business in 2011 was a mixed bag of serious market hurdles and fresh opportunities for innovation, depending on who you ask.

Many small businesses struggled to navigate a lackluster economy in which millions remained jobless and the outlook for consumer confidence and companies’ confidence in hiring and investing remained generally bleak.

24. Cross Creek Shopping Ctr. Sells for $12.7 Million - Tuesday, November 22, 2011

3469 Riverdale Road, 3505 Riverdale Road and 3587 Riverdale Road
Memphis, TN 38115
Sale Amount: $12.7 million

25. Deal Closes on $2.6M Sale of Highland Row Property - Monday, November 21, 2011

Worthington Hyde Partners, working under the name Highland Row Land Partners LLC, has bought the 13 acres of vacant land slated to become Highland Row from Poag & McEwen Lifestyle Centers – Memphis LLC for $2.6 million. The deal closed Thursday, Nov. 17.

26. GTx Posts $9.3M Q3 Loss - Monday, November 07, 2011

Memphis-based GTx Inc. reported Friday, Nov. 4, a $9.3 million loss for the third quarter as the company ramped up research and development on two drugs in clinical development programs.

27. GTx Posts $9.3M Q3 Loss - Friday, November 04, 2011

Memphis-based GTx Inc. reported Friday, Nov. 4, a $9.3 million loss for the third quarter as the company ramped up research and development on two drugs in clinical development programs.

28. Plotting a Course - Monday, September 19, 2011

State and federal officials are developing new programs and legislation to bolster small businesses.Many companies are facing a variety of hurdles in a lackluster economy in which millions remain jobless and the outlook for consumer confidence and companies’ confidence in hiring and investing remain bleak. But what shape those hurdles have taken depends on who you ask.

29. UTHSC Unveils New Pharmacy College - Thursday, August 25, 2011

For more than a century, the University of Tennessee Health Science Center College of Pharmacy has served as center of pharmacy education, practice and research in the Mid-South.

And on the eve of UTHSC’s September Centennial Gala, the College of Pharmacy – previously housed in six buildings on the sprawling, urban campus on Madison Avenue – is finally getting a home of its own.

30. GTx Reports Net Loss of $10.7M - Wednesday, August 10, 2011

Memphis-based pharmaceutical company GTx Inc. reported Tuesday, Aug. 9, a net loss of $10.7 million in the second quarter compared with a net loss of $12.9 million for the same period in 2010.

31. GTx Reports Q2 Loss of $10.7M - Tuesday, August 09, 2011

Memphis-based pharmaceutical company GTx Inc. reported Tuesday, Aug. 9, the company saw a net loss of $10.7 million in the second quarter, compared with a net loss of $12.9 million for the same period in 2010.

32. GTx Offers 10 Million Shares - Friday, June 24, 2011

Memphis-based biotechnology company GTx Inc. on Thursday, June 23, announced it is pricing 10 million shares of stock offered to the public at $4.75 per share.

33. GTx Inc., FDA to Begin Trials on Cancer Drug - Monday, June 13, 2011

GTx Inc., a Memphis-based pharmaceutical company, has announced an agreement with the U.S. Food and Drug Administration to begin Phase III clinical trials to evaluate Ostarine, a drug designed to prevent and treat muscle wasting in cancer patients.

34. KIPP Memphis Hosts Dress for Success Day - Friday, May 06, 2011

On Friday from 10 a.m. to 11 a.m., Memphis middle school students from KIPP (Knowledge is Power Program) DIAMOND Academy, 230 Henry St., will host Dress for Success Day, where students dressed in business attire will ask community leaders questions concerning their fields of work.

35. GTx, Ipsen Terminate Drug Collaboration - Thursday, March 03, 2011

Memphis biopharmaceutical startup GTx Inc. said Wednesday it and French-based pharmaceutical giant Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

36. GTx, Ipsen Terminate Drug Collaboration - Wednesday, March 02, 2011

Memphis biopharmaceutical startup GTx Inc. said Wednesday it and French-based pharmaceutical giant Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

37. GTx Reports Q4 Loss, but 2010 Profit - Friday, February 25, 2011

Memphis-based biopharmaceutical company GTx Inc. Thursday reported a $7.5 million net loss in the fourth quarter, but posted a $15.3 million profit for the full-year, ended Dec. 31.

38. GTx Reports Q4 Loss, But 2010 Profit - Thursday, February 24, 2011

Memphis-based biopharmaceutical company GTx Inc. Thursday reported a $7.5 million net loss in the fourth quarter, but posted a $15.3 million profit for the full-year, ended Dec. 31.

39. GTx Reports Q4, Full-Year Financial Results - Thursday, February 24, 2011

GTx, Inc. (Nasdaq: GTXI) today provided a company update and reported financial results for the fourth quarter and full year 2010.

40. GTx Therapy Shows Promise in Prostate Cancer Treatment - Tuesday, December 14, 2010

Clinical trials of Capesaris, a drug developed by Memphis-based GTx Inc., have shown promise in the treatment of advanced prostate cancer. The findings were presented this past weekend at the Annual Meeting of the Society of Urologic Oncology in Bethesda, Md.

41. GTx Cuts Loss, Gets More Capital - Wednesday, November 10, 2010

Memphis-based GTx Inc. completed its public offering of additional stock with help from another major investment by Joseph R. “Pitt” Hyde III.

42. GTx Cuts Loss, Gets More Capital - Tuesday, November 09, 2010

Memphis-based GTx Inc. completed its public offering of additional stock with help from another major investment by Joseph R. “Pitt” Hyde III.

43. GTx Receives Government Grants - Thursday, November 04, 2010

GTx Inc. has been awarded $1.2 million in federal grants from the Qualifying Therapeutic Discovery Project Program.

The $1 billion program was established by the Patient Protection and Affordable Care Act, the health care reform law.

44. GTx, Needing Cash, Issues More Stock - Thursday, October 28, 2010

Memphis-based GTx Inc. will issue more stock in a bid to shore up its operating reserves.

The biopharmaceutical company needs more money to finance clinical trials and have working capital, according to a filing it made this week with the U.S. Securities and Exchange Commission.

45. UTHSC Signs on for Eli Lilly Initiative - Friday, October 01, 2010

The University of Tennessee Health Science Center is participating in a research program initiated by Eli Lilly and Co. to get first dibs on potential drug therapies.

46. GTx Announces Positive News for Drug - Thursday, September 16, 2010

GTx has announced that tests of a drug it is developing show its “potential as a new hormonal treatment for advanced prostate cancer,” according to Mitchell Steiner, CEO of the Memphis-based biopharmaceutical company.

47. GTx’s Loss Widens on News of Abandoned Drug - Tuesday, August 10, 2010

The write-off of investments related to the development of a drug that didn’t pan out caused GTx Inc. to have a bigger loss during the second quarter.

48. GTx’s Loss Widens on News of Abandoned Drug - Monday, August 09, 2010

The write-off of investments related to the development of a drug that didn’t pan out caused GTx Inc. to have a bigger loss during the second quarter.

49. Study: Drug Helped Women Without Side Effects - Tuesday, June 22, 2010

Ostarine, a drug that Memphis-based GTx Inc. is developing for cancer wasting, was noted to have improved body mass and leg strength in the first study conducted exclusively on postmenopausal women.

50. Hyde Increases Stake In GTx Stock - Friday, June 11, 2010

Joseph R. “Pitt” Hyde III, the largest shareholder of Memphis-based biopharmaceutical company GTx Inc., continues to increase his stake in the company.

51. Study: GTx Drug Shows Promise - Wednesday, June 09, 2010

A midstage Phase IIb study of the GTx Inc. drug Ostarine shows that the drug therapy helps cancer patients with fatigue and anorexia who are suffering from muscle wasting, the Memphis-based biopharmaceutical company said.

52. GTx CEO Upbeat Despite Drug Setback - Friday, May 28, 2010

Dr. Mitch Steiner, the chief executive officer of GTx Inc., said the company is moving ahead with the other drug therapies it is developing after one intended to prevent prostate cancer did not show significant results in a clinical study.

53. GTx Faces Setback With Drug Trial - Thursday, May 27, 2010

GTx Inc. has reported a setback with one of the potential drug therapies in its pipeline, a treatment to prevent prostate cancer in men at high risk for the disease.

54. Powerful Possibilities - Monday, May 17, 2010

Oct. 29 turned into a day for window staring when the news came.

The top executives of GTx Inc. looked at the bleak gray of an overcast sky from the seventh floor of the Toyota Center, their minds gone blank.

55. Daily News Recognized for State’s Best Website - Tuesday, May 11, 2010

The Daily News Online and Senior Reporter Andy Meek took top honors in the annual Associated Press state awards over the weekend.

56. Memphis Daily News Scores TAPME Awards - Monday, May 10, 2010

The Daily News Online was named the best website among Division 4 newspapers in the annual TAPME (Tennessee Associated Press Managing Editors) awards Saturday evening in Nashville.

And Daily News Senior Reporter Andy Meek won the Malcolm Law Investigative Reporting Award for his coverage of Consulting Services Group (CSG), a consultant to Shelby County government on its pension fund investments.

57. GTx Reports $44.3M Net Income - Wednesday, May 05, 2010

GTx Inc. is pressing ahead with the development of a drug for muscle wasting in cancer patients after ending its partnership with Merck.

58. GTx CEO Addresses Ipsen Partnership - Thursday, March 25, 2010

The chief executive officer of GTx has learned a thing or two about partnerships as the Memphis-based biopharmaceutical company has struggled for profitability.

In the span of a week, GTx announced it was ending its two-and-a-half year partnership with Merck & Co. It then expanded its partnership with another pharmaceutical giant, Ipsen, of France.

59. GTx Affirms Partnership With Ipsen - Wednesday, March 24, 2010

A week after ending its partnership with Merck & Co., Memphis-based GTx Inc. confirmed an expansion of its partnership with French pharmaceutical giant Ipsen.

60. GTx, Merck Part Ways - Tuesday, March 16, 2010

Memphis-based GTx Inc. has ended its partnership with Merck & Co. to develop a drug to prevent wasting and muscle loss in cancer patients.

61. 2010 - Monday, January 04, 2010

Is it over yet? That may be the most frequently asked question in the New Year. “It” is the worst national economic recession since the Great Depression.

Accurately reading the indicators will not be easy. Some will predict the recession is about to end, just as new indicators point to continuing economic agony for thousands of Memphians.

62. GTx Lays Off 28 Pct. of Work Force - Tuesday, December 15, 2009

GTx on Friday laid off 28 percent of its work force, a reduction that is a direct result of the U.S. Food and Drug Administration’s decision on Oct. 30 to not grant approval of a drug the Memphis-based company is developing.

63. UPDATE: GTx Announces Lay-Offs - Friday, December 11, 2009

GTx said today it laid off 28 percent of its work force, a reduction that is a direct result of the U.S. Food and Drug Administration’s decision on Oct. 30 to not grant approval of a drug the Memphis-based company is developing.

64. GTx Releases Earnings Report, Touts Other Drugs - Tuesday, November 10, 2009

What a difference a week makes.

Seven days after explaining why the U.S. Food and Drug Administration did not approve its first drug product, Memphis-based GTx Inc. hosted a second conference call Monday when it reported earnings for the third quarter.

65. GTx Receives ‘Complete Surprise’ From Food and Drug Admin - Tuesday, November 03, 2009

The stock of Memphis-based GTx Inc. plunged 45 percent Monday morning after the company explained why the U.S. Food and Drug Administration did not grant approval for its drug to prevent bone fractures in men with prostate cancer who are undergoing hormone deprivation treatment.

66. FDA Approval of GTx Drug Could Come Today - Friday, October 30, 2009

The U.S. Food and Drug Administration is expected to announce today whether it will approve the use of a GTx Inc. drug to help prevent bone fractures in prostate cancer patients undergoing treatment with testosterone deprivation therapy.

67. GTx Progresses With Drug Therapy - Tuesday, September 15, 2009

The independent Data Safety Monitoring Board has recommended that GTx continue as planned the Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men considered at high risk for the disease.

68. GTx CEO Rings Bell To Open NASDAQ Trading - Friday, September 11, 2009

Dr. Mitch Steiner, the chief executive officer of Memphis-based GTx Inc., rang the bell to start stock trading on the NASDAQ Thursday morning.

69. GTx Reports Smaller Net Loss in Q2 - Tuesday, August 11, 2009

Memphis-based biopharmaceutical company GTx Inc. provided a timetable for the rollout of potential new therapies Monday when it released its second quarter earnings report.

The company, which is about to transition from the research and development phase to marketing new therapies, had a net loss of $11.3 million for the quarter compared to a net loss of $13.2 million for the same period a year ago. GTx, which has no debt, also said it has cash on hand of $68.9 million.

70. Baldwin Joins Visible School As Department Chair, Professor - Wednesday, July 29, 2009

George Baldwin has been hired by Visible School as department chair and assistant professor of music business ministry and audio production.

71. State Venture Fund Established For High-Growth Startups - Wednesday, July 15, 2009

Gov. Phil Bredesen last week signed into law legislation that will provide venture money for new companies with high growth potential, such as those involved in biotechnology and other innovations.

72. GTx Inc. Starts Trial for New Drug - Wednesday, July 08, 2009

GTx Inc. has initiated a phase 1 multiple ascending dose clinical trial evaluating a new drug for first-line treatment of advanced prostate cancer. A phase 1 single ascending dose clinical trial in 96 subjects was completed in June.

73. Study: GTx Drug For Muscle Wasting Shows Promise - Friday, June 12, 2009

A clinical trial of a GTx Inc. drug for muscle wasting in cancer patients shows benefits, according to a report the Memphis-based company released Thursday.

74. GTx Prepares for Market Launch - Tuesday, May 12, 2009

GTx Inc. is exploring whether to hire its own sales force or partner with another entity as it prepares to transition from a company almost exclusively involved in research and development to one with its own products.

75. UTHSC Professor Dagogo-Jack Appointed A.C. Mullins Chair - Wednesday, April 29, 2009

Samuel Dagogo-Jack has been appointed to the A.C. Mullins chair in Translational Research, an endowed professorship, at the University of Tennessee Health Sciences Center. Dagogo-Jack has also been named chief of the Division of Endocrinology for the Department of Medicine in the College of Medicine.

76. GTx Releases Bone Fracture Study - Tuesday, April 28, 2009

Nearly one in four men with prostate cancer being treated with androgen deprivation therapy suffered bone fractures or had critical bone loss, Memphis-based GTx Inc. reported Monday.

77. GTx to Present Clinical Trial Data - Thursday, April 23, 2009

GTx Corp. reported Wednesday that it will present data from the clinical trial of a new drug Sunday during the 2009 Annual Meeting of the American Urological Association in Chicago.

78. Former GTx Employee Sues Over Stock Option - Monday, April 06, 2009

While executives at Memphis-based GTx Inc. continue to exercise stock options in advance of the possible release of new drug therapies, a former employee of the pharmaceutical company is suing in federal court for her right to cash in any windfalls.

79. Merck to Buy Schering-Plough - Tuesday, March 10, 2009

The company that Abe Plough founded in Memphis no longer will bear his name under terms of a $41.1 billion merger announced Monday between Merck & Co. Inc. and Schering-Plough Corp.

80. GTx: FDA Will Rule On Bone Drug By Oct. - Friday, March 06, 2009

GTx Inc. reported Thursday that the U.S. Food and Drug Administration plans to make a ruling on the company’s bone drug toremifene by Oct. 30.

81. GTx Starts Trial For New Drug - Tuesday, February 24, 2009

GTx Inc. reported Monday it has initiated Phase 1 clinical trial of GTx-758, another drug to treat men with advanced prostate cancer.

82. GTx’s Bone Fracture Drug Under FDA Review - Thursday, February 19, 2009

Biopharmaceutical company GTx Inc. said Wednesday the U.S. Food and Drug Administration is reviewing its application for the drug candidate toremifene.

83. GTx Plans to Hire 65 Salespeople, Posts Losses - Wednesday, February 18, 2009

GTx will hire up to 65 pharmaceutical salespeople this year once the company hears back from the U.S. Food and Drug Administration about a regulatory review of toremifene for the prevention of bone fractures in men with prostate cancer who are on androgen deprivation therapy.

84. Schuler Buys Stake in GTx - Tuesday, February 03, 2009

Jack Schuler, an investor who has held top leadership posts in the pharmaceutical and biotech industries, last week purchased 8.3 percent of the shares of GTx Inc. for himself, his foundation and his children.

85. UTHSC’s Miller Honored For Medicinal Chemistry Work - Monday, February 02, 2009

Dr. Duane D. Miller has been inducted into the American Chemistry Society’s Medicinal Chemistry Hall of Fame.

Miller, a professor at the University of Tennessee Health Science Center and an executive with GTx, co-discovered and first described in medical literature a new class of drugs, selective androgen receptor modulators (SARMS), which have the potential to treat muscle wasting and other musculoskeletal conditions.

86. GTx Loses $13.9M In Fourth Quarter - Wednesday, January 28, 2009

Memphis-based GTx had net losses of $13.9 million for the fourth quarter and $51.8 million for the year, both ended Oct. 31, the company has reported.

The pharmaceutical company, which is close to the point of marketing new drug therapies, had cash on hand of $97.7 million.

87. GTx Addresses Change On Drug Label - Monday, January 26, 2009

Memphis-based GTx Inc. discussed with investors on Friday the label change for Fareston (toremifene citrate) 60 mg by the European Medicines Agency.

88. GTx, UT Foundation Reach Agreement - Tuesday, January 06, 2009

GTx Inc. and the University of Tennessee Research Foundation have reached an agreement in a dispute over income from a drug therapy, the company said in a filing with the Securities and Exchange Commission.

89. GTx Submits FDA Application For New Drug - Friday, January 02, 2009

Memphis-based GTx announced Tuesday morning that it had submitted a new drug application with the U.S. Food and Drug Administration for the prevention of bone fractures in men undergoing drug therapy for prostate cancer.

90. UTHSC Professors Receive Patents - Wednesday, December 17, 2008

Sixteen professors at the University of Tennessee Health Science Center who turned laboratory experiments into practical applications have received patents for innovations in medicine.

Besides the potential for better ways to diagnose the sick and injured, these innovations could provide a revenue stream for UTHSC.

91. UTHSC Profs Seek Greater Share From Research Foundation - Tuesday, December 16, 2008

Some of the University of Tennessee Health Science Center professors in Memphis whose discoveries have generated revenue for the UT Research Foundation are pressing for a greater share of its grants.

92. GTx Outlines Drug Pipeline - Friday, November 07, 2008

Executives at Memphis-based GTx on Thursday morning explained a promising pipeline of potential drug therapies that are moving closer to FDA approval and attracting investment partnerships from big pharmaceutical companies.

93. Vorder-Bruegge Combines Technology Passion With Practice - Thursday, November 06, 2008

Mark Vorder-Bruegge Jr. is a partner at Wyatt, Tarrant & Combs LLP, where he heads the Intellectual Property Protection & Litigation Service team. He also is the partner in charge of firm technology.

94. GTx Announces Conference Presentation - Wednesday, November 05, 2008

GTx reported Tuesday that its management will present a company overview Monday at the Rodman & Renshaw 10th Annual Healthcare Conference in New York.

The presentation will begin at 4:05 p.m. A simultaneous webcast of the presentation will be accessible from the investor relations section of the company’s Web site at www.gtxinc.com. An archived replay will be available on the site until Nov. 24.

95. GTx Stock Price Could Double - Wednesday, October 29, 2008

The stock price of Memphis-based GTx Inc. should double within the next year, according to a recent report in Investor’s Business Daily.

96. Sept. Commercial Sales Drop 18% - Monday, October 27, 2008

Shelby County’s commercial real estate market was highlighted by a wide variety – but a low volume – of transactions in September, revealing a continued slowdown because of the credit crisis and overall economic slowdown.

97. Extensive Rehab Planned For Frayser Apartments - Tuesday, September 30, 2008

2881 Range Line Road
Memphis, TN 38127
Permit Amount: $2.6 Million

Project Cost: $2.6 million
Permit Date: Applied September 2008
Completion: Spring 2009
Owner: Rynard Properties Ridgecrest LP
Tenant: Rynard Properties Ridgecrest LP
Contractor: R.L. Rynard Construction Inc.

98. Carwashes, Oil Change Shops Sell for $2.9M - Tuesday, September 23, 2008

Mark C. Johnson and Timothy A. Michelotti have sold the remainder of their oil change/carwash portfolio to Sunshine Carwash Partners LLC for $2.9 million. This latest round of transactions included the GTX 10-Minute Oil Change shops at 1675 Union Ave. and 6975 U.S. 64 (Stage Road). Both locations also had Sunshine Carwash franchises on site.

99. GTx Reports $13.2 Million Loss - Wednesday, August 06, 2008

GTx, Inc. reported a net loss of $13.2 million for the second quarter and $26 million for the six months, which ended June 30.

The net losses for the same period last year were $9.2 million and $17.3 million.

100. GTx Reports Q1 Net Loss of $12.7M - Tuesday, May 13, 2008

GTx Inc. has reported a net loss for the first quarter ended March 31 of $12.7 million, compared to a net loss of $8.1 million for the same period in 2007.

Revenue for the first quarter of 2008 was $4.5 million, compared to $1.7 million for the same period in 2007. Revenues for the first quarter of 2008 included $257,000 of net sales of Fareston, a drug marketed for the treatment of metastatic breast cancer in postmenopausal women, and $4.2 million of revenue from collaborations with Ipsen Limited and Merck & Co. Inc.